Charles River Laboratories International Signs $470M M&A Deal with Frontage Holdings Corporation
Charles River Laboratories has entered into definitive agreements to acquire Frontage Holdings Corporation’s bioanalysis and DMPK operations in Exton, Pennsylvania for $470 million in cash. The deal includes up to $75 million in additional contingent payments and is intended to expand Charles River's clinical bioanalysis capabilities to support clients across the full drug development lifecycle. The transaction is expected to close in the first half of 2027.
For the three months ended September 26, 2026, Charles River Laboratories reported total revenue of $982.7 million, a slight decrease from $1.00 billion in the prior year. Despite the revenue dip, net income attributable to common shareholders rose significantly to $333.1 million, primarily driven by a substantial income tax benefit of $163.8 million.
Charles River Laboratories International Financial Results
Charles River Laboratories reported Q3 2026 revenue of $982.7 million and organic revenue growth of 4.7%, marking its second consecutive quarter of organic growth. The company increased its full-year 2026 guidance for both revenue and non-GAAP earnings per share, driven by outperformance in its Discovery and Safety Assessment (DSA) segment.
Term
Q3 2026
“Our third-quarter results were highlighted by a return to organic revenue growth for the second consecutive quarter and significant margin expansion, which drove non-GAAP earnings per share growth of 27%. We were pleased with the performance of our DSA and Manufacturing segments, which both delivered organic revenue growth and improved profitability.”
James C. Foster, Chairman, President and Chief Executive Officer
Charles River Laboratories International Insider James C. Foster Sells $8.41M of Stock
James C. Foster sold 24,042 shares of Charles River Laboratories International, Inc. at $350.00 a share, worth $8.41M in total on Oct 22, 2026. Shares held after the trade: 31,596 (-43.2%).
Charles River Laboratories International CEVP, Disc & Safety Assessment Shannon M. Parisotto Sells $743K of Stock
Shannon M. Parisotto, CEVP, Disc & Safety Assessment, sold 2,156 shares of Charles River Laboratories International, Inc. at $344.41 a share, worth $743K in total on Oct 21, 2026. Shares held after the trade: 4,807 (-31.0%).